BAMF Health and Calyx/Invicro have entered a strategic partnership to address the drawbacks of fragmented service ecosystems, which cause redundant efforts, slow knowledge transfer, and longer development times. The partnership aims to accelerate the clinical translation of radioligand therapies (RLT) and immuno-oncology (IO) agents.

By merging Calyx/Invicro's radiochemistry and imaging biomarker solutions with BAMF Health's radiopharmacy facility, the companies aim to solve duplicative efforts and lengthy development processes. This will provide a complete resource to translate advanced programs into clinical trials efficiently. A key venture driving this partnership is an actinium-225 project, which includes the study and application of actinium-225 in RLT, leveraging its GE HealthCare StarGuide SPECT/CT and dosimetry expertise.

BAMF Health specializes in advanced molecular imaging and targeted therapy, utilizing state-of-the-art AI-enabled technology to diagnose and treat diseases like cancer, Alzheimer's, and cardiovascular conditions. The company uses theranostics, which combines diagnostic imaging with targeted therapy to provide highly personalized and effective treatments​. Its key offerings include United Imaging uEXPLORER total-body PET/CT, a high-resolution scanner claimed to provide a full-body scan in five minutes.

Analyst QuickTake: In March 2024 , Calyx and Invicro agreed to combine the companies through an acquisition, where Calyx would obtain complete ownership of Invicro from the previous owner, REALM IDx.